Labetalol hypertension study
Executive Summary
Report compiled by medical economist Gerry Oster of Brookline, Mass.-based Policy Analysis Inc. concludes that the alpha-beta blocker is more cost-effective than the beta blocker propanolol in treating black adults with mild-to-moderate hypertension. Oster maintains that for every 1,000 patients on monotherapy, those taking labetalol would have two to seven fewer strokes over a 10-year period, depending on age and sex, with a $190-$212 reduction in the yearly cost of treatment compared to propranolol. Oster reported the findings at a March 22 science writers seminar in New York City. Labetolol is marketed in the U.S. by Glaxo under the Trandate brand and by Schering as Normodyne.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.